Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Neuronetics, Inc.NASDAQ: STIM

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -$1.8M, compared with -$1.68M a year earlier. Trailing-twelve-month other income / expenses was -$7.83M.

Context

  • Other income / expenses amounted to 5.1% of revenue in FY2025, down 7.2 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$1.8M or moves back toward the trailing-twelve-month quarterly average of -$1.96M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.8M+16.3% QoQ
Last fiscal yearDec 2025
-$7.56M+17.6% YoY
LTMMar 2026
-$7.83M+20.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.2%——
1 year+17.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(7.56M) USD
Year-over-year change
+17.6%

Other Income / Expenses vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +20.6% is the 4th highest of 10, against a peer median of -41.2%.
  • Other income / expenses amounts to 5.2% of revenue for STIM, versus a peer median of 7.7%.
STIM Competitors
Other Income / Expenses for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$7.57M USD-41.2%+161.3%1225.4%
OABIOmniAb, Inc.LTM Mar 2026$4.56M USD+71.8%+107.2%15.8%
NYXHNyxoah S.A.LTM Mar 2026€1.25M EUR+265.9%—7.6%
OSUROraSure Technologies, Inc.LTM Mar 2026-$208K USD-104.2%—0.2%
PROFProfound Medical Corp.LTM Mar 2026-$611.96K USD-101.2%—3.2%
CDXSCodexis, Inc.LTM Mar 2026-$6.03M USD+17.5%—7.7%
STIMNeuronetics, Inc.LTM Mar 2026-$7.83M USD+20.6%—5.2%
ATLNAtlantic International Corp.LTM Dec 2025-$9.16M USD+91.5%—2.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$13.7M USD-653.1%—39.6%
PREPrenetics Global LimitedLTM Mar 2026-$35.09M USD-262.9%—30.8%
Peer median (excluding STIM) —-41.2%+134.3%7.7%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M65.21M71.35M74.89M149.16M
Cost of Revenue11.65M15.48M19.64M20.73M76.85M
Gross Profit43.66M49.72M51.71M54.16M72.31M
Gross Margin78.9%76.3%72.5%72.3%48.5%
Research & Development7.92M9.34M9.52M12.77M6.58M
Selling, General & Admin63.3M75.5M72.74M75.95M97.16M
Operating Expenses71.22M84.83M82.26M88.72M103.74M
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
EBITDA(26.81M)(31.96M)(22.76M)(34.37M)(27.12M)
EBITDA Margin-48.5%-49.0%-31.9%-45.9%-18.2%
Operating Income(27.56M)(35.11M)(30.55M)(34.56M)(31.44M)
Operating Margin-49.8%-53.8%-42.8%-46.2%-21.1%
Interest Income0024K00
Interest Expense3.3M3.6M5.42M7.29M8.42M
Other Income / Expenses(3.61M)(2.1M)365K(9.18M)(7.56M)
Income Before Tax(31.17M)(37.21M)(30.19M)(43.74M)(39M)
Pre-Tax Margin-56.4%-57.1%-42.3%-58.4%-26.1%
Income Tax Expense00(24K)(14K)0
Net Income(31.19M)(37.16M)(30.19M)(43.71M)(39M)
Net Margin-56.4%-57.0%-42.3%-58.4%-26.1%
EPS (Basic)(1.22)(1.38)(1.05)(1.38)(0.59)
EPS (Diluted)(1.22)(1.38)(1.05)(1.38)(0.59)
Weighted Avg Shares25.48M26.9M28.66M31.73M65.95M
Weighted Avg Shares (Diluted)25.48M26.9M28.66M31.73M65.95M

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.